DoW Lung Cancer Idea Development Award
The DoW Lung Cancer Idea Development Award funds innovative, early-stage research with high potential to advance lung cancer treatment, including a separate category for new investigators, requiring preliminary feasibility data.
Funder: Dept. of the Army -- USAMRAA
Due Dates: June 23, 2026: Pre-Application (Preproposal) deadline | July 30, 2026: Invitation to submit full application (notification) | September 2, 2026: Full application deadline | September 4, 2026: End of application verification period
Funding Amounts: ~$6.4M total; up to $800,000 total costs per award (max 3 years); ~8 awards expected.
Summary: Supports innovative, high-risk/high-reward research to accelerate progress toward eradicating deaths and suffering from lung cancer.
Key Information: Clinical trials are NOT allowed; research must address at least one FY26 LCRP Area of Emphasis.
Description
This opportunity supports conceptually innovative, high-risk/high-reward research projects that could lead to major advancements in lung cancer research and patient outcomes. The mechanism is designed to fund early-stage ideas with the potential to yield impactful data and open new avenues of investigation. Research must address at least one of the FY26 Lung Cancer Research Program (LCRP) Areas of Emphasis, such as biology, prevention, detection, treatment, or survivorship related to lung cancer (excluding mesothelioma). The program includes a New Investigator category, allowing early-career faculty to compete separately from established investigators. All proposals must include preliminary data, though these do not have to be derived from lung cancer studies.
